Drugs / Bretisilocin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07604558 | May → Sep 2026 overdue | — | AbbVie | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bretisilocin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07604558 ↗ |
| Route | Intramuscular | “bretisilocin intramuscular (IM) injection” NCT07604558 ↗ |